Published in Breast Cancer Res Treat on September 29, 2010
Concurrent chemoradiotherapy for locally advanced breast cancer-time for a new paradigm? Curr Oncol (2015) 1.14
Recurrence and survival after pathologic complete response to preoperative therapy followed by surgery for gastric or gastrooesophageal adenocarcinoma. Br J Cancer (2011) 1.01
Evaluation of breast cancer using intravoxel incoherent motion (IVIM) histogram analysis: comparison with malignant status, histological subtype, and molecular prognostic factors. Eur Radiol (2015) 0.90
Future directions for monitoring treatment responses in breast cancer. J Cancer (2014) 0.87
Pathological complete response in younger and older breast cancer patients. Arch Med Sci (2012) 0.86
DEGRO practical guidelines for radiotherapy of breast cancer V: Therapy for locally advanced and inflammatory breast cancer, as well as local therapy in cases with synchronous distant metastases. Strahlenther Onkol (2015) 0.85
The role of a prone setup in breast radiation therapy. Front Oncol (2011) 0.83
Locally advanced breast cancer - strategies for developing nations. Front Oncol (2015) 0.80
The numbers of FoxP3+ lymphocytes in sentinel lymph nodes of breast cancer patients correlate with primary tumor size but not nodal status. Cancer Invest (2011) 0.79
High Expression of Pyruvate Kinase M2 is Associated with Chemosensitivity to Epirubicin and 5-Fluorouracil in Breast Cancer. J Cancer (2015) 0.78
Response to: "Current definition of locally advanced breast cancer". Curr Oncol (2015) 0.75
Perioperative chemotherapy for gastroesophageal cancer in British Columbia: a multicentre experience. Curr Oncol (2014) 0.75
Results of a phase I-II study of adjuvant concurrent carboplatin and accelerated radiotherapy for triple negative breast cancer. Oncoimmunology (2016) 0.75
Comparison of two radiation techniques for the breast boost in patients undergoing neoadjuvant treatment for breast cancer. Br J Radiol (2016) 0.75
Neoadjuvant chemotherapy in borderline resectable pancreatic cancer: A case report. Oncol Lett (2017) 0.75
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13.90
let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell (2007) 13.69
The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res (2007) 11.56
Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol (2003) 11.11
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol (2008) 11.03
Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res (2005) 9.70
Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol (1998) 9.32
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A (2009) 7.95
Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol (1999) 7.59
Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol (2007) 7.00
Tumor self-seeding by circulating cancer cells. Cell (2009) 6.66
Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol (2008) 6.31
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol (1999) 5.65
Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res (2007) 4.41
Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol (2005) 3.83
Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol (2006) 3.58
Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol (2002) 3.29
Systemic effects of local radiotherapy. Lancet Oncol (2009) 2.97
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol (2002) 2.89
Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol (1998) 2.59
Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study. J Clin Oncol (2004) 2.58
Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer (2004) 2.38
Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst (2008) 2.35
Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol (2005) 1.99
Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol (2003) 1.96
Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res (1986) 1.82
Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. J Clin Oncol (2004) 1.72
Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast. Cancer (1994) 1.61
Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2). Ann Oncol (2005) 1.58
American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome. J Natl Cancer Inst (2005) 1.49
Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation. Clin Cancer Res (2010) 1.43
Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study. J Clin Oncol (2009) 1.36
Neoadjuvant concurrent paclitaxel and radiation in stage II/III breast cancer. Clin Cancer Res (2006) 1.34
Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol (1999) 1.25
Concurrent mitomycin C, 5-fluorouracil, and radiotherapy in the treatment of locally advanced carcinoma of the cervix: a randomized trial. Int J Radiat Oncol Biol Phys (2003) 1.18
Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study. J Clin Oncol (2005) 1.15
Preoperative twice-weekly paclitaxel with concurrent radiation therapy followed by surgery and postoperative doxorubicin-based chemotherapy in locally advanced breast cancer: a phase I/II trial. J Clin Oncol (2003) 1.07
Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice. Cell Immunol (2010) 1.01
Effects of chemoradiation on tumor-host interactions: the immunologic side. J Clin Oncol (2008) 1.00
Phase II study of neoadjuvant paclitaxel and cisplatin for operable and locally advanced breast cancer: analysis of 126 patients. Br J Cancer (2004) 0.95
Enhanced interaction between tubulin and microtubule-associated protein 2 via inhibition of MAP kinase and CDC2 kinase by paclitaxel. Int J Cancer (1995) 0.93
A Phase II trial of neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin in the treatment of patients with locally advanced breast carcinoma. Cancer (1998) 0.89
Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer. Ann Oncol (2005) 0.84
Original p53 status predicts for pathological response in locally advanced breast cancer patients treated preoperatively with continuous infusion 5-fluorouracil and radiation therapy. Int J Radiat Oncol Biol Phys (1997) 0.83
Combined sequential approach in locally advanced breast cancer. Ann Oncol (1999) 0.82
A phase II trial of a neoadjuvant platinum regimen for locally advanced breast cancer: pathologic response, long-term follow-up, and correlation with biomarkers. Clin Breast Cancer (2009) 0.82
Retrospective analysis of locally advanced noninflammatory breast cancer from Chennai, South India, 1990-1999. Int J Radiat Oncol Biol Phys (2007) 0.81
Immunological aspects of local radiotherapy: clinical relevance. Discov Med (2010) 0.80
Pre-operative chemotherapy and radiotherapy in breast cancer. Eur J Cancer (1998) 0.78
Neoadjuvant chemotherapy with infusional 5-fluorouracil, adriamycin and cyclophosphamide (iFAC) in locally advanced breast cancer: an early response predicts good prognosis. Ann Oncol (2005) 0.78
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest (2011) 14.22
EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol (2008) 5.46
Translational control in cancer. Nat Rev Cancer (2010) 4.59
Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res (2009) 4.58
Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys (2004) 4.29
Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res (2005) 4.23
Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol (2007) 4.06
The Delta Np63 alpha phosphoprotein binds the p21 and 14-3-3 sigma promoters in vivo and has transcriptional repressor activity that is reduced by Hay-Wells syndrome-derived mutations. Mol Cell Biol (2003) 3.00
The enigmatic X gene of hepatitis B virus. J Virol (2004) 2.98
Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. J Clin Oncol (2012) 2.85
Cadmium mimics the in vivo effects of estrogen in the uterus and mammary gland. Nat Med (2003) 2.77
IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J Exp Med (2011) 2.74
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat (2011) 2.73
Significance of p63 amplification and overexpression in lung cancer development and prognosis. Cancer Res (2003) 2.70
Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol (2007) 2.63
Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J Immunol (2008) 2.61
Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: a treatment planning comparison. Int J Radiat Oncol Biol Phys (2007) 2.55
A hypoxia-controlled cap-dependent to cap-independent translation switch in breast cancer. Mol Cell (2007) 2.44
Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol (2008) 2.43
Induction by transforming growth factor-beta1 of epithelial to mesenchymal transition is a rare event in vitro. Breast Cancer Res (2004) 2.33
A tale of two proteins: differential roles and regulation of Smad2 and Smad3 in TGF-beta signaling. J Cell Biochem (2007) 2.32
Prone vs supine positioning for breast cancer radiotherapy. JAMA (2012) 2.32
Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res (2013) 2.30
Combining radiotherapy and immunotherapy: a revived partnership. Int J Radiat Oncol Biol Phys (2005) 2.29
eIF4GI links nutrient sensing by mTOR to cell proliferation and inhibition of autophagy. J Cell Biol (2008) 2.26
Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. J Clin Oncol (2008) 2.15
Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys (2009) 2.07
Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res (2003) 2.04
Essential role for eIF4GI overexpression in the pathogenesis of inflammatory breast cancer. Nat Cell Biol (2009) 1.99
Survival in familial dysautonomia: Impact of early intervention. J Pediatr (2002) 1.98
GRP78 as a novel predictor of responsiveness to chemotherapy in breast cancer. Cancer Res (2006) 1.96
Transforming growth factor-beta and microRNA:mRNA regulatory networks in epithelial plasticity. Cells Tissues Organs (2007) 1.95
mRNA decay factor AUF1 maintains normal aging, telomere maintenance, and suppression of senescence by activation of telomerase transcription. Mol Cell (2012) 1.86
A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species. Cancer Res (2006) 1.85
Cost and utilization outcomes of patients receiving hospital-based palliative care consultation. J Palliat Med (2006) 1.85
Loss of p63 leads to increased cell migration and up-regulation of genes involved in invasion and metastasis. Cancer Res (2006) 1.84
Oncogenic beta-catenin is required for bone morphogenetic protein 4 expression in human cancer cells. Cancer Res (2002) 1.82
Inhibition of integrin alpha(v)beta6, an activator of latent transforming growth factor-beta, prevents radiation-induced lung fibrosis. Am J Respir Crit Care Med (2007) 1.79
Selective degradation of AU-rich mRNAs promoted by the p37 AUF1 protein isoform. Mol Cell Biol (2003) 1.79
Radiation as an immunological adjuvant: current evidence on dose and fractionation. Front Oncol (2012) 1.76
Hypoxia inhibits protein synthesis through a 4E-BP1 and elongation factor 2 kinase pathway controlled by mTOR and uncoupled in breast cancer cells. Mol Cell Biol (2006) 1.76
Endotoxic shock in AUF1 knockout mice mediated by failure to degrade proinflammatory cytokine mRNAs. Genes Dev (2006) 1.74
Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol (2014) 1.74
Characterization of matriptase expression in normal human tissues. J Histochem Cytochem (2003) 1.74
Dexmedetomidine for awake carotid endarterectomy: efficacy, hemodynamic profile, and side effects. J Neurosurg Anesthesiol (2004) 1.73
TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer. Cancer Inform (2012) 1.72
Biologic comparison of partial breast irradiation protocols. Int J Radiat Oncol Biol Phys (2004) 1.71
p63: Molecular complexity in development and cancer. Carcinogenesis (2004) 1.69
Endothelin receptor type B gene promoter hypermethylation in salivary rinses is independently associated with risk of oral cavity cancer and premalignancy. Cancer Prev Res (Phila) (2010) 1.68
BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition. Clin Cancer Res (2013) 1.66
Squamous cell carcinoma of the oral cavity in nonsmoking women: a new and unusual complication of chemotherapy for recurrent ovarian cancer? Oncologist (2012) 1.65
New strategies for triple-negative breast cancer--deciphering the heterogeneity. Clin Cancer Res (2014) 1.65
Tissue distribution of AU-rich mRNA-binding proteins involved in regulation of mRNA decay. J Biol Chem (2004) 1.63
The DNA binding activity of p53 displays reaction-diffusion kinetics. Biophys J (2006) 1.61
Comparative study of exome copy number variation estimation tools using array comparative genomic hybridization as control. Biomed Res Int (2013) 1.61
Nutritional control of mRNA stability is mediated by a conserved AU-rich element that binds the cytoplasmic shuttling protein HuR. J Biol Chem (2002) 1.61
Stat5a is tyrosine phosphorylated and nuclear localized in a high proportion of human breast cancers. Int J Cancer (2004) 1.60
Ethical, legal, and social issues related to genomics and cancer research: the impending crisis. J Am Coll Radiol (2005) 1.60
Intraperitoneal therapy for stage III ovarian cancer: a therapy whose time has come! J Clin Oncol (2002) 1.56
Tumor necrosis factor alpha inhibition of hepatitis B virus replication involves disruption of capsid Integrity through activation of NF-kappaB. J Virol (2003) 1.55
Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects. J Clin Invest (2012) 1.55
In vitro effects of the BH3 mimetic, (-)-gossypol, on head and neck squamous cell carcinoma cells. Clin Cancer Res (2004) 1.55
Nuclear import and export functions in the different isoforms of the AUF1/heterogeneous nuclear ribonucleoprotein protein family. J Biol Chem (2003) 1.54
Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov (2013) 1.54
Fludrocortisone in patients with familial dysautonomia--assessing effect on clinical parameters and gene expression. Clin Auton Res (2005) 1.52
Regulation of protein synthesis by ionizing radiation. Mol Cell Biol (2009) 1.52
The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas. Clin Cancer Res (2006) 1.51
Prone accelerated partial breast irradiation after breast-conserving surgery: preliminary clinical results and dose-volume histogram analysis. Int J Radiat Oncol Biol Phys (2004) 1.51
Nanotechnology-based drug delivery systems. J Occup Med Toxicol (2007) 1.50
Is surgical excision necessary for the management of atypical lobular hyperplasia and lobular carcinoma in situ diagnosed on core needle biopsy?: a report of 38 cases and review of the literature. Arch Pathol Lab Med (2008) 1.49
Hepatitis B virus DNA replication is coordinated by core protein serine phosphorylation and HBx expression. J Virol (2005) 1.47
Development and validation of a method for using breast core needle biopsies for gene expression microarray analyses. Clin Cancer Res (2002) 1.47
Activation of signal transducer and activator of transcription 5 in human prostate cancer is associated with high histological grade. Cancer Res (2004) 1.47
Ubiquitin-dependent mechanism regulates rapid turnover of AU-rich cytokine mRNAs. Proc Natl Acad Sci U S A (2002) 1.46
Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer. Clin Cancer Res (2012) 1.46
Deregulated estrogen receptor alpha expression in mammary epithelial cells of transgenic mice results in the development of ductal carcinoma in situ. Cancer Res (2005) 1.46
Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters. Clin Cancer Res (2002) 1.44
Increased frequency of regulatory T cells in peripheral blood and tumour infiltrating lymphocytes in colorectal cancer patients. Cancer Immun (2007) 1.43
A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer. Clin Cancer Res (2003) 1.43
Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation. Clin Cancer Res (2010) 1.43
In regard to Kao et al.: concomitant radiation therapy and paclitaxel for unresectable locally advanced breast cancer: results from two consecutive phase I/II trials (Int J Radiat Oncol Biol Phys 2005;61:1045-1053). Int J Radiat Oncol Biol Phys (2005) 1.38